PSP001 - A First-in-disease human PEGIFN-λ Chimera
-
Prosit Sole innitiated a First-in-humans study of the safety, tolerability, and pharmacokinetics of PSP001, a new type of immunomodulator form family Interfon Lambda2024-07-04First-in-humansstudyofthesafety,tolerability,andpharmacokineticsofACT-451840,anewchemicalentitywithantimalarialactivity.
-
Feb. 03, 2021, FDA approved IND filing and Sigle Ascending Dose trial may Proceed2023-04-06